Login
Companies $ERAS
$15.11 +$0.00 (0.0%) After hours
Erasca, Inc. logo

Erasca, Inc.

erasca.com

What Do They Do?

Develops precision cancer therapies for patients with cancers driven by the RAS/MAPK pathway, including RAS-targeting drugs and an EGFR antibody.

Who Are Their Customers?

Its intended customers are patients with RAS/MAPK pathway-driven cancers; the company is developing drug candidates and has not yet begun product sales.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −68% (Loss)
vs −$30.6M in Q3 FY2025
  • Aug 24, 2026 FDA granted ERAS-0015 Fast Track Designation for pancreatic cancer The designation concerns treatment of patients with metastatic pancreatic adenocarcinoma.
  • Jul 13, 2026 Erasca reported updated Phase 1 data and planned trials for ERAS-0015 The update included preliminary responses and development plans for pancreatic, lung and colorectal cancers.
  • Apr 27, 2026 Revolution Medicines alleged patent infringement and trade-secret misappropriation Revolution Medicines demanded that Erasca stop certain ERAS-0015 activities; Erasca said it would contest the allegations.

Portfolio focus The older report described candidates against several cancer cell signals, while the latest centers its clinical work on medicines targeting RAS and KRAS, retains an EGFR antibody in discovery, and says it stopped developing naporafenib.

Who Do They Compete With?

Competes with Adlai Nortye, Amgen, Boehringer Ingelheim, BridgeBio Oncology Therapeutics, Bristol Myers Squibb, Eli Lilly, GenFleet Therapeutics, Jacobio Pharmaceuticals, Merck, Pfizer, Revolution Medicines, and Roche/Genentech

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support